Xanodyne Pharmaceuticals (Roxicodone) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Xanodyne Pharmaceuticals (Roxicodone) General Information

Description

Oxycodone hydrochloride tablets in 5, 15 and 30 mg dosage strengths. Roxicodone is an immediate release formulation of oxycodone indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. It is marketed in the United States.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 1 Riverfront Place
  • Newport, KY 41071
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xanodyne Pharmaceuticals (Roxicodone) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xanodyne Pharmaceuticals (Roxicodone)‘s full profile, request access.

Request a free trial

Xanodyne Pharmaceuticals (Roxicodone) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xanodyne Pharmaceuticals (Roxicodone)‘s full profile, request access.

Request a free trial